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Abstract: The drugs based on platinum metals represent one of the oldest, but also one of 
the most effective groups of chemotherapeutic agents. Thanks to many clinical studies it is 
known that resistance of tumor cells to drugs is a frequent cause of chemotherapy failure. 
With  regard  to  platinum  based  drugs,  multidrug resistance can also  be connected with 
increased expression of low-molecular weight protein metallothionein (MT). This study 
aimed  at  investigating  the  interactions  of  MT  with  cisplatin  or  carboplatin,  using  the 
adsorptive transfer technique coupled with differential pulse voltammetry Brdicka reaction 
(AdTS DPV Brdicka reaction), and a comparison of in vitro results with results obtained in 
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vivo. The results obtained from the in vitro study show a strong affinity between platinum 
based drugs and MT. Further, we analyzed extracts of neuroblastoma cell lines treated with 
cisplatin or carboplatin. It is clear that neuroblastoma UKF-NB-4 cisplatin-resistant and 
cisplatin-sensitive  cell  lines  unlikely  respond  to  the  presence  of  the  platinum-based 
cytostatics cisplatin and carboplatin. Finally, we determined the level of MT in samples 
from  rabbits  treated  with  carboplatin  and  patients  with  retinoblastoma  treated  with  the  
same drug. 
Keywords:  tumor disease; metallothionein; platinum based anticancer drugs; anticancer 
therapy; resistance; retinoblastoma 
 
1. Introduction 
From a contemporary point of view, the process of the origin of malignant tumors is complex and 
multifactorial, comprising changes in expression of individual genes, physical factors and exposure to 
different chemical and biological impulses. Research and development in the field of tumor diagnostics 
and prevention, as well as methods of modern therapeutic approaches, belong to the priorities of all 
European Union countries. Individual tumor treatment strategies result from a number of treatment 
protocols combining an economic point of view and maximum benefit for the patient. One of the most 
important  parts  of  the  therapy  is  an  efficacious  chemotherapy  application  connected  with  the 
individualization of the therapy [1–10]. 
1.1. Cisplatin Based Chemotherapeutics  
Drugs based on platinum metals represent one of the oldest, but also one of the most effective 
groups of chemotherapeutic agents [11–21]. Platinum-complex based chemotherapeutics are presently 
used in the therapy of a broad-spectrum of malignancies. The biological activity of the first-time-used 
platinum-based cytostatic agent, cisplatin, was discovered in 1965 by Rosenberg during research of the 
electric current influence on bacteria growth [22]. Since then, hundreds of platinum complexes have 
been  synthesized  and  verified  as  anticancer  chemotherapeutics,  such  as  cisplatin,  carboplatin, 
oxaliplatin,  lobaplatin  and  ormaplatin,  belonging  to  the  best  known.  Though  cisplatin  has  been 
successfully  used  in  the  therapy  of  malignant  tumors  for  more  than  25  years,  its  biochemical 
mechanism  of  action  is  still  not  clear.  The  cytotoxic  effect  of  cisplatin  consists  in  DNA  adducts 
formation,  especially  to  guanine  and  adenine,  which  causes  DNA  strands  crossing  and  thereby 
inhibition  of  DNA  synthesis  and  consequently  mitosis.  The  therapeutic  effect  of  platinum-based 
therapeutics is permanently irreplaceable and brings considerable benefits to patients [23–30]. 
1.2. Tumor Therapy Resistance 
Thanks to many clinical research studies, it is known that resistance of tumor cells to drugs is a 
common  cause of chemotherapy failure. This  resistance develops via various mechanisms and the 
whole  process  is  multifactorial  at  the  cell  level.  Treatment  of  complications  caused  by  multidrug Int. J. Mol. Sci. 2010, 11                       
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resistance  (MDR)  is  particularly  difficult.  One  of  the  causes  of  tumor  cell  resistance  is  lowered 
therapeutic concentration of the cytostatic agent(s) in the target site. Membrane proteins such as Pgp, 
MRP and LRP participate in decreasing the cytostatics level in tumor cells. The complexity of MDR 
origination is also supported by changes in expression of genes participating in apoptosis or tumor 
suppressor  genes.  Cytostatics  detoxification  can  be  another  factor  leading  to  MDR,  in  which  an 
increased  activity of enzymes involved in  oxidation  or conjugation of xenobiotics with  endogenic 
agents are most frequently found. In addition to these mechanisms, MDR can be also connected with 
the  increased  expression  of  low-molecular  weight  protein  metallothionein  
(MT) [12,17–20,23,24,26,27,30–36].  
1.3. Metallothionein Significance 
Metallothionein (MT) belongs to the group of intracellular, cysteine-rich proteins (Cys content up to 
30% of the molecule) with a molecular weight of 6–10 kDa. The MT molecule consists of two binding 
domains composed of two cysteine clusters. The N-terminal part of the protein (β-domain) has three 
binding sites for divalent ions and the C-terminal protein part (α-domain) is able to bind four divalent 
metal ions. One MT molecule is able to bind 12 univalent and/or seven divalent metal ions. However, 
it is known that single MT molecules differ in their metal ions content and, thus, heavy metal binding 
sites in the MT molecule are not saturated under physiological conditions [37,38]. This is important for 
MT  biological  function  (heavy  metals  homeostasis  and  detoxification,  immunomodulation  and 
regulation functions) [35,36,39,40]. One of the most important MT feature is its ability to interact with 
metal-containing therapeutics, such as platinum-based cytostatics. This ability can result in a decrease 
of the free cytostatic agent therapeutic level and thereby increase the resistance of tumor cells against 
cytostatic agent therapeutic concentrations. A review in Current Protein and Peptide Science aimed at 
clarifying the relationship between MT and tumor diseases was recently published [35]. Figure 1 shows 
a  simplified  scheme  of  interaction  between  MT  and  platinum-based  cytostatics. Platinum-based 
therapeutic agents are probably able to bind to metal transcription inhibitor (MTI) that consequently 
releases  the  metal  transcription  factor-1  (MTF-1).  Herewith,  the  MT  biosynthesis  is  initiated  and 
biosynthesized MT can interact with platinum-based cytostatic agent molecules. Thanks to inactivation 
of  executive  free  therapeutic  molecules  by  MT,  the  cytostatic  agent  therapeutic  concentrations 
decreases and this leads to the growth of new cell subpopulations resistant to tumor therapy. The 
mechanisms  of this process are still not clear  [11,30,31,35,41–53]. This present study is aimed at 
studying  interactions  of  metallothionein  and  cisplatin  or  carboplatin  using  the  adsorptive  transfer 
technique coupled with differential pulse voltammetry Brdicka reaction (AdTS DPV Brdicka reaction). 
We also aim to compare in vitro results with results obtained in vivo. Particularly, attention is paid to 
analysis  of  in  vitro  experiments,  neuroblastoma  cell  line  extracts,  blood  from  rabbits  treated with 
carboplatin, and patients with retinoblastoma treated with the same drug. 
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Figure 1. Simplified scheme of the interactions of MT with platinum-based cytostatics.  
(a) Application of platinum based cytostatic agents into organisms; (b) transport into the 
cell nucleus, (c) binding of platinum based cytostatic agents to metal transcription inhibitor 
(MTI) and release from complex with metal transcription factor-1 (MTF-1) followed by 
MTF-1  binding  to  metal  responsive  element  (MRE).  This  step  initiates  mRNA  MT 
synthesis. mRNA is consequently translated and active MT bind molecules of platinum-
based cytostatics. 
 
2. Results and Discussion 
2.1. Significance of Thiol Compounds in Resistance Origination 
It is known that thiol compounds play a very important role in the processes linked to the formation 
of tumor cell resistance to platinum-based cytostatics [35,54,55]. Recently, we suggested a unique Int. J. Mol. Sci. 2010, 11                       
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electrochemical  technique enabling direct  MT  detection  in  blood  serum. This  method is  based on 
removal of interfering proteins by heat treatment and consequent adsorption of metallothionein to the 
surface of the working electrode [56,57]. 
2.2. Study of Platinum-Based Therapeutics Interactions with Metallothionein Modified Electrode  
In the first in vitro experiment, we targeted the monitoring of cisplatin and carboplatin interactions 
with MT. We utilized an adsorptive transfer technique differential pulse voltammetry coupled Brdicka 
reaction (AdTS DPV Brdicka reaction) for this purpose. This technique has been successfully used for 
MT determination in numerous samples [57–60] and excellent correlation between immunochemical 
techniques was found [55,61]. The scheme of the experimental arrangement for the interaction studies 
is shown in Figure 2. A hanging mercury drop electrode (HMDE) was immersed in a 5 µL drop of MT 
for  120  s  (point  1  and  2),  after  unbound  molecules  were  released  (3),  the  modified  HMDE  was 
immersed into a drop with a cytostatic agent (4). Then the electrode was carefully rinsed with water 
and analyzed (6) with computer treatment of the data obtained (7). Modification of the electrode and 
other experimental conditions were optimized in our previously published paper [62]. 
Figure 2. Scheme of study of the interaction between platinum-based cytostatics and MT. 
The MT molecule is composed of two domains containing cysteine clusters capable of 
binding metal ions. The hanging mercury drop electrode (HMDE) was immersed in a 5 µL 
drop of MT for 120 s (1 and 2), and after release of unbounded molecules (3), modified 
HMDE was immersed into a drop of cytostatic agent (4), then carefully rinsed with water. 
Electrochemical measurements followed (6) with computer processing of the data (7). 
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MT  (0.4  µg/mL)  modified  HMDE  was  utilized  for  studying  its  interactions  with  cisplatin  and 
carboplatin.  For  both  compounds  we  obtained  characteristic  voltammograms  (Figure  3).  It  clearly 
follows from the obtained results that the catalytic signal Cat2 diminished with increasing interaction 
time. After 20 min, the Cat2 signal decreased by more than 60% for both cytostatics. With increasing 
interaction times, no decrease of the signal was observed. For both drugs similar results were obtained, 
but the decrease of the signal was more rapid for cisplatin; where after 15 min interaction no further 
decrease of the signal was observed. For carboplatin, the decrease of the signal was slower and the 
lowering  of  the  signal  was  complete  after  20  min  interaction.  Similar  results  were  obtained  for 
interactions  between  cisplatin  or  carboplatin  drugs,  but  a  more  distinct  Cat2  signal  decrease  was 
observed after 10 min interaction for carboplatin and after 5 min for cisplatin (Figure 4). 
Figure 3. AdTS DP voltammograms of MT modified HMDE in the presence of the active 
cytostatic substances carboplatin (left panel) and cisplatin (right panel). MT and platinum-
based cytostatics concentration 0.4 µg/mL; interaction time of MT with HMDE 120 s. 
 
 
The observed differences in the Cat2 signal decrease indicate that the studied compounds have 
different  affinities  for  MT,  probably  due  to  their  chemical  structures.  Differences  between  active 
substances  and  pharmaceutical  drugs  are  probably  caused  by  the  presence  of  adjuvants  in 
pharmaceutical drugs that significantly change their physicochemical properties (ionic strength, pH). 
Some of these parameters were investigated in our previous experiments [48], the obtained knowledge 
is possible to utilize for MT detection via hydrogen evolution. We can assume which platinum-based 
therapeutics (cisplatin, carboplatin) were captured by MT anchored onto HMDE surface and we were 
able to observe only changes directly connected with MT - drug interactions. In addition, El-Hourch et 
al.  published  the  utilization  of  cisplatin  for  hydrogen  evolution  from  supporting  electrolyte  [63]. 
However,  platinum  ions  were  not  in  the  supporting  electrolyte,  thus  they  could  not  influence  the 
catalytic  reaction.  The  arrangement  of  the  experiment  also  unambiguously  points  at  the  fact  that 
carboplatin and cisplatin were strongly bound to the MT structure. Int. J. Mol. Sci. 2010, 11                       
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Figure  4.  AdTS  DP  voltammograms  of  MT  modified  HMDE  in  the  presence  of 
pharmaceutical therapeutics containing cytostatic substances carboplatin (left panel) and 
cisplatin  (right  panel).  MT  and  platinum-based  cytostatics  concentration  
0.4 µg/mL; time of interaction MT with HMDE 120 s. 
 
2.3. Changes in Cell Cultures 
As it was demonstrated in our previous experiment in vitro, MT very rapidly and effectively binds 
platinum-based cytostatics (cisplatin and carboplatin). However, experiments carried out in vitro do not 
show the behavior of the analyzed compounds in an organism. Therefore, experiments in vivo were 
carried  out  to  elucidate  the  significance  of  MT  for  resistance  origination  after  the  treatment  by 
platinum-based therapeutics. 
2.4. Automated Detection of Metallothionein 
For  routine  analysis  of  larger  sets  of  samples,  an  automated  electroanalytical  method  for  MT 
determination was found [48]. Reproducibility of determination varied within the range of 96 to 99% 
(n = 30). Dependence of studied MT signal height was linear in the concentration interval 0.1–5 µM. In 
our  preliminary  experiment,  we  demonstrated  that  the  MT  level  increases  in  the  presence  of  
platinum-based  cytostatics  according  to  the  applied  concentration.  Differences  between  cisplatin-
resistant and cisplatin-sensitive tumor cell lines were also determined [48,55].  
We were further interested in studying the time-dependence of these changes in greater detail. We 
compared the effect of cisplatin and carboplatin in concentrations of 0.01, 0.1 and 1 µM on resistant 
and sensitive tumor cell lines derived from neuroblastoma - UKF-NB-4. Cell lines were cultivated for 
0.5, 1, 2, 4, 6, 12, 24 and 48 h in the presence of platinum-based cytostatic drugs such as cisplatin and 
carboplatin. At the end of the experiment, cells were homogenized and consequently MT level was 
determined in cell lysates using the procedure shown in [48].  Int. J. Mol. Sci. 2010, 11                       
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Sensitive  cell  lines  demonstrated  a  significant  growth  depression  in  the  presence  of  cytostatic 
agents. MT level was significantly increased in all sensitive  tumor cell lines by about 50–90% in 
comparison with the control cell line. As it is well evident from Figure 5, the MT level increased in 
resistant tumor cell lines compared to sensitive cells. In the resistant tumor cell lines, the increase of 
MT level was dependent on the cytostatic agent used and its concentration. With carboplatin, changes 
in MT level were observable from the beginning of the experiment, whereas under the two highest 
carboplatin concentrations the MT level was significantly increased in resistant tumor cells compared 
to sensitive ones. In the case of the cisplatin-resistant tumor cell line, the MT level increase was firstly 
observable  after  six  hours  of  treatment.  This  increase  was  consequently  followed  by  a  moderate 
decrease in comparison with the resistant tumor cell line, whose maximum MT level was well evident 
already in the first hours of the experiment. Then, MT level relatively rapidly decreased to that of the 
values of sensitive tumor cell lines. Fluctuation in MT after cisplatin as well as carboplatin exposition 
with a similar development in the presence of all applied concentrations can be interpreted by initiatory 
free MT saturation by cytostatic agent  and its  resulting elimination from  cells,  which  results  in a 
decrease of MT level in cells. Resistant tumor cell lines, in contrast to the sensitive ones, responded to 
the cytostatic agent presence by significantly enhancing MT expression, which was well evident as a 
rapid increase of the MT level. Determined differences in MT levels during platinum-based cytostatics 
treatment  are  in  good  agreement  with  our  knowledge  about  cytostatics  detoxification  via  thiol 
compounds that increase the ability of these tumor cell lines to survive in the presence of platinum-
based  therapeutics.  From  the  obtained  results,  it  clearly  follows  that  neuroblastoma  
UKF-NB-4  cisplatin-resistant  and  cisplatin-sensitive  cell  lines  unlikely  respond  to  the  presence  of 
platinum-based cytostatics cisplatin and carboplatin. 
2.5. Changes of MT Level in Rabbits after Intravitreal Carboplatin Administration  
Retinoblastoma is one of the most frequent intraocular malignant tumors and it is the malignancy 
with the highest incidence in children. Retinoblastoma genesis is connected with gene mutation of both 
alleles  of  the  retinoblastoma  gene  RB1  localized  on  chromosome  13q1.4.  Its  therapy  is  still  very 
difficult,  thus,  new  therapeutic  possibilities  as  well  as  new  ways  of  cytostatics  application  are 
intensively searched. One of these applications is direct injection of cytostatics—in this case especially 
carboplatin—into  the  eye.  For  this  purpose,  carboplatin  was  applied  to  experimental  animals  and 
consequently MT level was determined using automated electrochemical detection. Figure 6 shows the 
changes in MT levels according to the length of the carboplatin treatment. At the beginning, the MT 
level was about 3.5 µM in healthy rabbits. After carboplatin application, a significant increase in the 
MT level was determined in all experimental animals up to 5 µM. An enhanced MT level was detected 
for the following seven days in all experimental animals. A slight decrease in MT level was observed 
14 days after carboplatin application. From the obtained results, it clearly follows that MT level was 
induced  by  carboplatin  application  directly  into  the  eyes  and  can  be  probably  connected  with  the 
resistance origination. Int. J. Mol. Sci. 2010, 11                       
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Figure 5. Neuroblastoma cell culture. Dependence of MT level in cell lines on the length 
of the cultivation. Prior to use in this experiment, all cell lines were cultivated for five  
sub-cultivations  without  cytostatics  addition.  Then,  neuroblastoma  cell  cultures  were 
exposed to cisplatin (left) or carboplatin (right). 
 
Figure 6. Time-dependent changes in concentrations of MT in the plasma of rabbits treated 
with carboplatin. The increase of MT levels is observed after injection of drug. PK RV 
(peripheral blood from right ventricle) has always higher MT concentration than PK LV 
(peripheral blood from right ventricle). Typical DP voltammogram of plasma analysis is 
shown on the right side. 
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2.6. MT Changes in Retinoblastoma Patients  
Retinoblastoma is a very rare malignant disease in the Czech Republic. Its treatment is centralized 
into a specialized workplace: FN Motol, Prague. Samples of retinoblastoma patients (n = 2) treated 
long-term with carboplatin were analyzed. Figure 7 shows the changes in MT level during long-term 
therapy in relation to the time-dependent changes after cytostatic agent application. MT levels were 
monitored 4 or 24 hours after application of the drug and the same procedure was repeated after a few 
days during the next treatment with carboplatin. In short-time monitoring of MT concentrations, a 
higher  increase  was  observed  with  each  dose  of  carboplatin;  nevertheless,  long  periods  had  a 
stabilization effect on MT levels in the plasma after carboplatin application.  
Figure  7.  Time-dependent  changes  in  the  concentration  of  MT  in  the  plasma  of  two 
patients  (a,  b)  with  retinoblastoma.  MT  levels  were  monitored  4  or  24  hours  after 
application of the drug and the same procedure was repeated after a few days during the 
next treatment with carboplatin. DP voltammograms are shown on the right. 
 
 
Immediately  after  carboplatin  application,  no  MT  level  increase  was  detected;  only  in  the  first 
minutes after application a moderate MT level decrease was determined. This is probably connected 
with the interaction with carboplatin and free MT. Three days after the first application of carboplatin, 
a moderate MT level  decrease (about  9%) was  observed in  comparison with the first application. 
Application after 27 days since the first application led to a significant MT level enhancement (165%) Int. J. Mol. Sci. 2010, 11                       
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compared to the first day. Maximal MT levels were determined between the 30
th and 60
th day after 
initial  carboplatin  application.  After  the  60
th  day  after  the first  carboplatin application, MT levels 
slowly decreased. Figure 7 shows characteristic voltammetric records of individual samples with well 
distinguishable signals. 
3. Experimental Section 
3.1. Chemicals and pH Measurements 
Rabbit liver MT (MW 7143), containing 5.9% Cd and 0.5% Zn, was purchased from Sigma Aldrich 
(St.  Louis,  MO, USA). Tris(2-carboxyethyl)phosphine (TCEP) was  produced by Molecular Probes 
(Evgen, Oregon, WI, USA). Other chemicals used were purchased from Sigma Aldrich. The stock 
standard  solutions  of  MT  at  10  μg/mL  with  1  mM  TCEP  were  prepared  with  ACS  water  
(Sigma-Aldrich, St. Louis, MO, USA) and stored in the dark at −20 ° C. Working standard solutions 
were prepared daily by dilution of the stock solutions. The pH was measured using pH meter WTW 
inoLab  (Weilheim,  Germany).  The  pH-electrode  (SenTix-H,  pH  0–14/3M  KCl)  was  regularly 
calibrated by a set of WTW buffers (Weilheim, Germany). 
3.2. Tumor Cell Lines 
The following cell lines obtained from the Department of Paediatric Haematology and Oncology, 
Charles University, Prague, Czech Republic were used: UKF-NB4—cisplatin or carboplatin sensitive 
(prepared  from  recurrence  of  neuroblastoma  into  bone  marrow,  with  MYCN  amplification,  del 
1p34.2ter, del 13iso 17q) and UKF-NB4—cisplatin or carboplatin resistant (the line derived from the 
previous line—UKF-NB4 with in vitro induced resistance to cisplatin or carboplatin). The cell lines 
were prepared by cultivation with increasing concentration of cisplatin or carboplatin. The cells were 
cultivated in IMDM medium with 10% fetal calf serum at 37 ° C, the chemoresistant cell lines were 
cultivated in medium with cisplatin or carboplatin added. 
3.3. Human Blood Serum 
The samples of blood were obtained using vein tapping to the closed tapping units without another 
reagent during medical treatment of two patients with malignancies at Teaching Hospital Motol, Czech 
Republic.  All  patients  subscribed  to  informed  consent  with  utilization  of  their  blood  samples  for  
the research. 
3.4. Preparation of the Samples for Electroanalytical Determination of Metallothionein 
3.4.1. Human Blood Serum  
Human blood serum samples were prepared by heat treatment and solvent precipitation. Briefly, 
samples were kept at 99 ° C in a thermomixer (Eppendorf 5430, USA) for 15 min with occasional 
stirring, and then cooled to 4 ° C. The denatured homogenates were centrifuged at 4 ° C, 15,000 ×  g for 
30 min (Eppendorf 5402, USA). Heat treatment effectively denatures and removes high molecular Int. J. Mol. Sci. 2010, 11                       
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weight proteins from samples [56]. Determination of MT in the human blood serum samples was 
performed by differential pulse voltammetry Brdicka reaction. Analyzed sample volume was 5 μL. 
3.4.2. Tumor Cell Lines  
The harvested cells were transferred to a test tube and deep frozen in liquid nitrogen to disrupt the 
cells. The frozen cells were mixed with extraction buffer (100 mM potassium phosphate, pH 8.7) to a 
final  volume  of  1  mL  and  homogenized  using  hand-operated  homogenizer  ULTRA-TURRAX  T8 
(IKA, Germany) placed in an ice bath for 3 min at 25,000 rpm. The homogenate was centrifuged at 
10,000 ×  g for 15 min and at 4 ° C (Eppendorf 5402, USA) [64]. The supernatant were processed in the 
same way as the human blood serum samples mentioned in Section 3.4.1. The processed samples were 
measured  by  adsorptive  transfer  stripping  technique  coupled  with  chronopotentiometric  
stripping analysis. 
3.4.3. Intravitreal Administration of Carboplatin in Rabbits  
Administration of carboplatin was performed according to data which indicate that periocular or 
intravitreal (transcorneal) carboplatin injections rather than systematically administrated carboplatin 
can effectively treat children with intraocular retinoblastoma. Six adult New Zealand White Rabbits 
(Anlab, Czech Republic) with an average weight of 2.45 kg (SD ±  0.38) were handled according to the 
statement Nr.207/2004 s.11 of the Ministry of Agriculture of the Czech Republic for the use of animals 
in experiments. In vivo experiments were further approved by the ethical committee for animal welfare 
of Charles University, 2nd Faculty of Medicine. The animals were kept at 22–25 C room temperature, 
at 55–65% relative air humidity, and on a 12 h light/dark cycle, and were provided with tap water and 
rabbit  chow  TM  MaK  1  (Bergman,  Kocanda,  Czech  Republic)  ad  libitum.  The  rabbits  were 
anesthetized intramuscularly with a mixture of 30–50 mg/kg of ketamine hydrochloride (Narketan 10, 
Vé toquinol, France) and 5 mg/kg of xylazine hydrochlorid (Rometar 2%., Spofa, Czech Republic) 
throughout  the  experiment.  Topical  oxybuprocaine  eye  drops  (0.4%,  Benoxi,  Unimed  Pharma, 
Slovakia) were used to anesthetize the ocular surface before intravitreal puncture.  
Carboplatin (Carboplatin, TEVA, Netherlands) solution was prepared immediately before injection 
by dissolving carboplatin in  sterile water with mannitol to  the final used concentrations. A single 
transcorneal intravitreal injection of carboplatin (0.05 mg in total volume of 0.1 mL) was applied with 
a 25-gauge needle into the right eye; the left eye of all animals served as uninjected controls. Blood 
samples were taken at 0, 6, 24 and 48 h, 7 and 14 days after injection. Blood samples were drawn from 
the  peripheral  auricular  vein  and  collected  in  tubes  with  ammonium  heparinate.  The  blood  was 
centrifuged at 3,000 rpm for 10 minutes to separate blood plasma.  
3.5. Electrochemical Measurements 
3.5.1. Electroanalytical Determination of Metallothionein  
An  adsorptive  transfer  stripping  technique  (AdTS)  coupled  with  DPV  Brdicka  reaction  was 
employed  for  the  determination  of  metallothionein  in  the  cell  lines  extracts.  The  electrochemical 
measurements  were  performed  using  an  AUTOLAB  analyzer  (EcoChemie,  The  Netherlands) Int. J. Mol. Sci. 2010, 11                       
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connected to  VA-Stand 663 (Metrohm,  Switzerland), using a standard electrochemical  cell with  a 
classical three-electrode connection. The three-electrode system consisted of a hanging mercury drop 
electrode  as  the  working electrode, an Ag/AgCl/3 M  KCl reference electrode and a glassy carbon 
auxiliary  electrode.  For  smoothing  and  baseline  correction,  the  software  GPES  4.9  supplied  by 
EcoChemie was employed. The Brdicka supporting electrolyte (1 mM Co(NH3)6Cl3 in 1 M ammonia 
buffer (NH3(aq) + NH4Cl, pH = 9.6) was used; no surface-active agent was added. AdTS DPV Brdicka 
reaction parameters were as follows: initial potential of −0.6 V, end potential −1.6 V, modulation time 
0.057 s, time interval 0.2 s, step potential of 1.05 mV, modulation amplitude of 250 mV, Eads = 0 V. 
Temperature of the supporting electrolyte was 4 ° C. 
3.5.2. Automated Electroanalytical Determination of Metallothionein  
Differential  pulse voltammetric Brdicka’s reaction measurements  were performed with  747 VA 
Stand instrument connected to 746 VA Trace Analyzer and 695 Autosampler (Metrohm, Switzerland), 
using a standard cell with three electrodes and a cooled sample holder (4 ° C). A hanging mercury drop 
electrode (HMDE) with a drop area of 0.4 mm
2 was the working electrode. An Ag/AgCl/3M KCl 
electrode was  the reference and glassy carbon electrode was  the auxiliary electrode. The software 
GPES 4.9 supplied by EcoChemie was employed for smoothing and baseline correction of the raw 
data.  The  analyzed  samples  were  deoxygenated  prior  to  measurements  by  purging  with  argon 
(99.999%), saturated with water for 120 s. The Brdicka’s supporting electrolyte containing 1 mM 
Co(NH3)6Cl3  and  1  M  ammonia  buffer  (NH3(aq)  +  NH4Cl,  pH  =  9.6)  was  used  and  after  each 
measurement the supporting electrolyte was exchanged. The parameters of the measurement were as 
follows: initial potential of −0.7 V, end potential of −1.75 V, modulation time 0.057 s, time interval 
0.2 s, step potential 2 mV, modulation amplitude −250 mV, Eads = 0 V. All experiments were carried 
out at 4 ° C employing thermostat Julabo F12 (Labortechnik GmbH, Germany). One hundred-times 
diluted sample with 0.1 M phosphate buffer pH 7.0 (20 µL) was used. 
3.6. Descriptive Statistics 
Data  were  processed  using  MICROSOFT  EXCEL®  (USA)  and  STATISTICA.CZ  Version  8.0 
(Czech Republic). Results are expressed as mean ±  standard deviation (S.D.) unless otherwise noted 
(EXCEL
®).  Statistical  significance  of  the  differences  between  MT  levels  and  rat  weight  were 
determined using STATISTICA.CZ. Differences with p < 0.05 were considered significant and were 
determined  using  one  way  ANOVA  test  (particularly  Scheffe  test),  which  was  applied  for  
means comparison. 
4. Conclusions 
Adsorptive transfer technique differential pulse voltammetry coupled with Brdicka reaction presents 
a unique possibility for studying interactions between proteins and cytostatics. Catalytic signals are 
very sensitive and enable the study of interactions at the nanomolar level. In addition, our in vivo 
experiments  verify  the  hypothesis  that  MT  levels  significantly  increase  after  platinum-based 
therapeutic application. In the case of platinum-resistant tumor cell lines, the MT level significantly Int. J. Mol. Sci. 2010, 11                       
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increases. Thus, MT can act as one of the factors of tumor therapy resistance. For understanding these 
mechanisms, experiments on experimental animals were carried out and in addition MT levels were 
monitored  in  patients  with  a  rare  malignant  disease—retinoblastoma—after  platinum-based  
cytostatics treatment. 
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